Comparison · NCT02842086-sae
Descovy (DVY) vs Truvada (TVD): serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Descovy (DVY) vs Truvada (TVD): serious adverse events. Trial comparisons, record NCT02842086-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02842086-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.075 | 0.0656 | 0.0855 | wilson | |
| Risk in group 2 | 0.0691 | 0.0601 | 0.0793 | wilson | |
| Risk difference, group 1 minus group 2 | 0.00591 | -0.00793 | 0.0198 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.09 | 0.896 | 1.32 | log | |
| Odds ratio, group 1 over group 2 | 1.09 | 0.888 | 1.34 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Descovy (DVY) than on Truvada (TVD) | 169 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Descovy (DVY) | DVY (F/TAF 200/25 mg) FDC tablet plus placebo-to-match TVD (F/TDF 200/300 mg) FDC tablet administered orally once daily for at least 96 weeks. | 202 | 2,694 | EG000 |
| Group 2 | Truvada (TVD) | TVD (F/TDF 200/300 mg) FDC tablet plus placebo-to-match DVY (F/TAF 200/25 mg) FDC tablet administered orally once daily for at least 96 weeks. | 186 | 2,693 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- First dose date up to the data cut for end of blinded treatment (maximum: 157 weeks)
Source ClinicalTrials.gov
Trial
- Title
Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection
- NCT number
- NCT02842086
- Phases
- PHASE3
- Conditions
- Pre-Exposure Prophylaxis of HIV-1 Infection
- Interventions
- F/TAF, F/TDF, F/TAF Placebo, F/TDF Placebo
- Lead sponsor
- Gilead Sciences
- Results first posted
- 2020-03-17
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02842086?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02842086-sae